基于癌症基因组图谱数据库分析芳香烃受体核转运体样2在肺腺癌中的表达及其预后意义

Abstract
Figure/Table
References (21)
Related Citation (9)

Download: PDF (0 KB) HTML (35 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the expression and clinical significance of aryl hydrocarbon receptor nuclear transporter-like 2 (ARNTL2) in lung adenocarcinoma and its paraccinomal tissues. Methods RNA seq data from 337 lung adenocarcinoma tissues (lung adenocarcinoma group) and 59 adjacent tissues (adjacent cancer control group) and corresponding clinical data from lung adenocarcinoma patients were downloaded from the Cancer Genome Atlas database.The relationship between ARNTL2 expression and lung adenocarcinoma patients was compared by univariate analysis,and multivariate analysis by Cox proportional risk model to judge independent risk factors affecting prognosis in lung adenocarcinoma patients. Results The expression of ARNTL2 in the lung adenocarcinoma group was higher than that in the adjacent cancer control group, and the difference was statistically significant (P＜0.05). The results of the univariate analysis showed that the age, Stage stage, and N stage of patients with lung adenocarcinoma were relevant factors affecting ARNTL2 expression (P ＜0.05). Results of the survival prognostic analysis revealed a correlation between ARNTL2 expression and overall survival in patients with lung adenocarcinoma (P=0.001). Results of the univariate analysis showed that Stage stage and ARNTL2 expression were associated factors affecting overall survival in patients with lung adenocarcinoma (P ＜0.05). Results of the Cox proportional hazards model showed that Stage stage and ARNTL2 expression were independent risk factors for overall survival in patients with lung adenocarcinoma (P＜0.05).Conclusion ARNTL2 may promote the development of lung adenocarcinoma through multiple pathways, which then affects the prognostic survival of patients with lung adenocarcinoma. Thus, ARNTL2 can serve as a prognostic marker or a potential therapeutic target in patients with lung adenocarcinoma.

Key words： Aryl hydrocarbon receptor nuclear transporter-like 2;Lung adenocarcinoma;Cancer Genome Atlas Prognostic marker

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Jin-hua
	ZHAO Qiu-rong
	YOU Jian-bin
	CHEN Fa-lin

Cite this article:

CHEN Jin-hua,ZHAO Qiu-rong,YOU Jian-bin, et al. Analysis of the expression and clinical significance of aryl hydrocarbon receptor nuclear transporter-like 2 in lung adenoarinoma utilizing the Cancer Genome Atlas datasets[J]. 中国当代医药, 2021, 28(30): 91-94.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I30/91

[1]	Sung H，Ferlay J，Siegel RL，et al.Global Cancer Statistics 2020：GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA Cancer J Clin，2021，71（3）：209-249.
[2]	Siegel RL，Miller KD，Jemal A.Cancer statistics，2016[J].CA Cancer J Clin，2016，66（1）：7-30.
[3]	Chen WQ，Zheng RS，Baade PD，et al.Cancer statistics in China 2015[J].CA Cancer J Clin，2016，66（2）：115-132.
[4]	江杭，金风.时钟基因的研究进展及临床应用[J].现代肿瘤医学，2017，25（4）：641-644.
[8]	Kelleher F C，Rao A，Maguire A.Circadian molecular clocks and cancer[J].Cancer Lett，2014，342（1）：9-18.
[11]	Hutter C，Zenklusen JC.The Cancer Genome Atlas：Creating L asting Value beyondIts Data[J].Cell，2018，173（2）：283-285.
[13]	Wang Z，Jensen MA，Zenklusen JC.A Practical Guide to The Cancer Genome Atlas （TCGA）[J].Methods Mol Biol，2016，1418：111-141.
[19]	吴天添，朱沛枫，吴康中，等.结肠癌多发肝转移病灶中Tra-2β、microRNA320α 基因与患者生存期的相关性研究[J].中国现代医生，2020，58（5）：1-5.
[5]	Sasaki M，Yoshitane H，Du NH，et al.Preferential inhibition of BMAL2-CLOCK activity by PER2 reemphasizes its negative role and a positive role of BMAL2 in the circadian transcription[J].J Biol Chem，2009，284（37）：25149-25159.
[6]	Hogenesch JB，Gu YZ，Moran SM，et al.The basic helix-loophelix-PAS protein MOP9 is a brain-specific heterodimeric partner of circadian and hypoxia factors[J].J Neurosci，2000，20（13）：83-90.
[7]	Mazzoccoli G，Pazienza V，Panza A，et al.ARNTL2 and SERPINE1：potential biomarkers for tumor aggressiveness in colorectal cancer[J].J Cancer Res Clin Oncol，2012，138（3）：501-511.
[9]	Polo A，Singh S，Crispo A，et al.Evaluating the associations between human circadian rhythms and dysregulated genes in liver cancer cells[J].Oncol Lett，2017，14（6）：7353-7359.
[10]	Wendeu-Foyet MG，Koudou Y，Cenee S，et al.Circadian genes and risk of prostate cancer：Findings from the EPICAP study[J].Int J Cancer，2019，145（7）：1745-1753.
[12]	Ding L，Bailey MH，Porta-Pardo E，et al.Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics[J].Cell，2018，173（2）：305-320.
[14]	Sanchez-Vega F，Mina M，Armenia J，et al.Oncogenic Signaling Pathways in The Cancer Genome Atlas[J].Cell，2018，173（2）：321-337.
[15]	Malta TM，Sokolov A，Gentles AJ，et al.Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation[J].Cell，2018，173（12）：338-354.
[16]	Wang Z，Liu T，Xue W，et al.ARNTL2 promotes pancreatic ductal adenocarcinoma progression through TGF/BETA pathway and is regulated by miR-26a-5p[J].Cell Death Dis，2020，11（8）：692.
[17]	Wang S，Ma X，Ying Y，et al.Upregulation of ARNTL2 is associated with poor survival and immune infiltration in clear cell renal cell carcinoma[J].Cancer Cell Int，2021，21（1）：341.
[18]	Lu M，Huang L，Tang Y，et al.ARNTL2 knockdown suppressed the invasion and migration of colon carcinoma：decreased SMOC2-EMT expression through inactivation of PI3K/AKT pathway[J].Am J Transl Res，2020，12（4）：1293-1308.
[20]	郎慧玲，刘晟男，钱甜甜，等.抑制JNK 通路对Genistein诱导结肠癌SW620 细胞周期阻滞的作用[J].中国现代医生，2019，57（34）：26-30.
[21]	应希旺，李亚清，冷报浪.ABT-737 逆转EGFR T790M 突变肺腺癌细胞EGFR-TKIs 耐药的机制研究[J].中国现代医生，2019，57（18）：9-14，19，169.